This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health 将来の成長

Future 基準チェック /26

現在、 BELLUS Healthの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

46.1%

収益成長率

41.4%

EPS成長率

Biotechs 収益成長	34.8%
収益成長率	69.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Jun 2023

今後の成長に関する最新情報

Recent updates

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07

業績と収益の成長予測

TSX:BLU - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	40	-147	-110	-64	3
12/31/2024	0	-141	-130	-127	3
12/31/2023	0	-117	-125	-101	2
3/31/2023	0	-87	-89	-89	N/A
12/31/2022	0	-76	-77	-77	N/A
9/30/2022	0	-73	-68	-68	N/A
6/30/2022	0	-71	-64	-64	N/A
3/31/2022	0	-70	-60	-60	N/A
12/31/2021	0	-71	-61	-61	N/A
9/30/2021	0	-64	-49	-49	N/A
6/30/2021	0	-47	-40	-40	N/A
3/31/2021	0	-37	-36	-36	N/A
12/31/2020	0	-32	-30	-30	N/A
9/30/2020	0	-34	-30	-30	N/A
6/30/2020	0	-35	-32	-32	N/A
3/31/2020	0	-33	-29	-29	N/A
12/31/2019	0	-26	-21	-21	N/A
9/30/2019	0	-18	-14	-14	N/A
6/30/2019	0	-14	-9	-9	N/A
3/31/2019	0	-9	-8	-8	N/A
12/31/2018	0	-7	-7	-7	N/A
9/30/2018	0	-6	-7	-7	N/A
6/30/2018	0	-5	-6	-6	N/A
3/31/2018	0	-4	-5	-5	N/A
12/31/2017	0	-1	-5	-3	N/A
9/30/2017	0	-1	-4	-3	N/A
6/30/2017	1	0	-3	-2	N/A
3/31/2017	1	0	-3	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	3	-1	N/A	-2	N/A
6/30/2016	3	0	N/A	-2	N/A
3/31/2016	3	0	N/A	-2	N/A
12/31/2015	3	0	N/A	-2	N/A
9/30/2015	2	0	N/A	-2	N/A
6/30/2015	2	-1	N/A	-2	N/A
3/31/2015	2	-1	N/A	-2	N/A
12/31/2014	2	-2	N/A	-3	N/A
9/30/2014	2	-2	N/A	-3	N/A
6/30/2014	2	-1	N/A	-4	N/A
3/31/2014	2	-1	N/A	-3	N/A
12/31/2013	2	-1	N/A	-3	N/A
9/30/2013	2	-1	N/A	-3	N/A
6/30/2013	2	-2	N/A	-3	N/A
3/31/2013	2	-10	N/A	-3	N/A
12/31/2012	2	-13	N/A	-3	N/A
9/30/2012	3	-15	N/A	-2	N/A
6/30/2012	3	-14	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BLU今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BLU今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BLU今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BLUの収益 ( 69% ) Canadian市場 ( 6.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: BLUの収益 ( 69% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BLUの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

This company has been acquired

BELLUS Health 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 40%, EPS downgraded

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Consensus revenue estimates fall by 93%

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

Recent updates

BELLUS Health Inc.(NasdaqGS:BLU) dropped from NASDAQ Composite Index

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

President exercised options to buy CA$35m worth of stock.

Consensus revenue estimates increase by 40%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Independent Lead Director recently sold CA$449k worth of stock

President exercised options and sold CA$3.1m worth of stock

Independent Director recently sold CA$433k worth of stock

Consensus revenue estimates fall by 93%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

First half 2022 earnings released

BELLUS Health Inc. Expects to Initiate A Phase 1 Clinical Trial Investigating A Once-Daily, Extended-Release Formulation of BLU-5937 in the Fourth Quarter of 2022

Bellus Health Inc. Announces Positive End-Of-Phase 2 Meeting with the FDA and Its Calm Phase 3 Program for BLU-5937 in Refractory Chronic Cough

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Senior Vice President of Finance recently sold CA$576k worth of stock

Chief Scientific Officer recently sold CA$951k worth of stock

BELLUS Health Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Consensus forecasts updated

Consensus revenue estimates increase by 16%

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Bellus Health Announces Positive Topline Results from Its Phase 2B Soothe Trial of Blu-5937 for the Treatment of Refractory Chronic Cough

Price target increased to CA$16.40

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.094 loss in 3Q 2020)

BELLUS Health Inc. Announces Completion of Patient Enrollment in Soothe Phase 2B Trial for Refractory Chronic Cough and Blueprint Phase 2A Trial for Chronic Pruritus Associated with Atopic Dermatitisz

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Price target increased to CA$10.70

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘